Noble Capital Markets Maintains Outperform on Unicycive Therapeutics, Lowers Price Target to $50
Noble Capital Markets analyst Robert LeBoyer maintains Unicycive Therapeutics (NASDAQ: UNCY ) with a Outperform and lowers the price target from $60 to $50.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.